

PET and prostate cancer: Jadvar provides perspective on the current status of molecular imaging of prostate cancer with PET, including assessment of a range of radiotracers and prospects for future development. . . . *Page 1685*

Response criteria in PRRT: van Vliet and colleagues compare tumor response assessment using 4 common criteria in patients with neuroendocrine tumors treated with ¹⁷⁷Lu-octreotate peptide receptor radionuclide therapy. . . . *Page 1689*

PET in breast cancer: Gemignani and colleagues describe correlation of ¹⁸F-FES PET with expression of estrogen and progesterone receptors in patients with primary, operable breast cancer. . . . *Page 1697*

Textural features in oropharyngeal cancer: Cheng and colleagues determine whether textural features in pretreatment ¹⁸F-FDG PET/CT can provide additional prognostic information over total lesion glycolysis and clinical staging in advanced oropharyngeal squamous cell carcinoma. . . . *Page 1703*

PET, ablative radiotherapy, and HCC: Huang and colleagues explore the utility of ¹⁸F-FDG PET and a combined ¹⁸F-FDG-contrast CT parameter for predicting tumor control in patients with hepatocellular carcinoma treated with stereotactic ablative radiotherapy. . . . *Page 1710*

^{99m}Tc-sestamibi and Gaucher disease: Erba and colleagues investigate the reliability of ^{99m}Tc-sestamibi scintigraphy in monitoring changes in bone marrow involvement induced by enzyme replacement therapy in patients with Gaucher disease. . . . *Page 1717*

PET and survival in osteosarcoma: Byun and colleagues explore the ability of metabolic and volumetric parameters on pretreatment ¹⁸F-FDG PET/CT as well as histologic and chemotherapeutic response to predict survival in patients with osteosarcoma of the extremities. . . . *Page 1725*

β-blockers and hemostasis in heart failure: de Peuter and colleagues use ¹²³I-MIBG imaging to compare cardiac sympathetic activity with selective and nonselective β-blockers in patients with heart failure and correlate results with serum markers for coagulability. . . . *Page 1733*

PET and abdominal aortic aneurysms: Courtois and colleagues compare ¹⁸F-FDG uptake in aneurysmal wall biopsies from patients with abdominal aortic aneurysms to determine whether PET can identify cellular and molecular changes predictive of deterioration and rupture. . . . *Page 1740*

Regadenoson ⁸²Rb cardiac PET: Hsiao and colleagues explore the diagnostic performance of regadenoson ⁸²Rb myocardial perfusion PET imaging in detection of obstructive coronary artery disease in patients with and without pretest likelihood of cardiac disease. . . . *Page 1748*

⁶⁸Ga-DOTATOC and ⁶⁸Ga-DOTATATE dosimetry: Sandström and colleagues document the comparative biodistributions and radiation dosimetry of these radiolabeled somatostatin analogs for PET imaging in patients with neuroendocrine tumors. . . . *Page 1755*

Novel A_{2A} receptor tracer: Tavares and colleagues describe the kinetic properties, test-retest results, and dosimetry estimates of a ¹²³I-labeled SPECT tracer for in vivo imaging of adenosine 2A receptors in the brain. . . . *Page 1760*

Improved AC for PET/MR: Bezrukov and colleagues assess the accuracy of 4 MR-based attenuation correction techniques for hybrid PET/MR imaging in lesions within soft tissue, bone, and MR susceptibility artifacts. . . . *Page 1768*

Radionuclide imaging in epilepsy: Kumar and Chugani provide an educational overview of current applications of PET and SPECT in presurgical evaluation of intractable seizures, including localizing epileptogenic regions, identifying dual pathologies, assessing secondary foci, and evaluating brain functional integrity. . . . *Page 1775*

Alternative to mice in tracer development: Warnock and colleagues demonstrate PET and CT imaging in a U87 glioblastoma tumor model grown on chicken chorioallantoic membranes as a rapid, inexpensive, and ethically sustainable alternative to mice in novel PET tracer research. . . . *Page 1782*

PulmoBind lung imaging: Létourneau and colleagues detail the design of and early

translational studies with a ^{99m}Tc-labeled adrenomedullin-based compound for molecular imaging of the pulmonary circulation. . . . *Page 1789*

^{99m}Tc GRPs in tumor imaging: Marsouvanidis and colleagues detail the development of a series of ^{99m}Tc-labeled demomedin C analogs and compare their performance in both in vitro and in vivo gastrin-releasing peptide receptor tumor models. . . . *Page 1797*

Metabolism of ¹¹C-PD153035: Samén and colleagues investigate the in vivo metabolic characteristics of this analog of an epidermal growth factor receptor tyrosine kinase inhibitor to determine whether alterations in metabolite formation are accompanied by changes in biodistribution and tumor uptake. . . . *Page 1804*

PET-compatible tissue bioreactor: Whitehead and colleagues detail the development of a tissue bioreactor enabling modulation of the microenvironment and integration of the reactor with a small-animal PET scanner to facilitate imaging biomarker and radiopharmaceutical research. . . . *Page 1812*

Microfluidic radioassay: Wang and colleagues describe the development and use of a portable radiopharmaceutical imaging platform designed to capture the kinetics of cellular responses to drugs. . . . *Page 1820*

nanoScan PET/MR performance: Nagy and colleagues evaluate the standards-based performance of this high-resolution integrated system for consecutive PET and MR imaging of small laboratory animals. . . . *Page 1825*

Inveon SPECT capabilities: Boisson and colleagues assess the performance metrics of this small-animal system using 3 dedicated collimators for imaging in mice and 3 for rats. . . . *Page 1833*

Radioluminescence microscopy and ¹⁸F-FDG uptake: Pratz and colleague report on a particle-counting method for improving spatial resolution and overcoming β-range limits in fluorescence microscopy imaging of radionuclide uptake by single cells. . . . *Page 1841*